MGTXライブシグナル | Getagraph.comで利益を最大化

売る 108137 min ago

@ $6.39

発行日: 14 2月 2024 @ 23:30

リターン: -22.85%

前回のシグナル: 2月 13 - 23:30

前回のシグナル: 買う

リターン: -2.44 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Stats
本日の出来高	27 903.00
平均出来高	148 182
時価総額	313.53M
EPS	$0 ( 2024-03-12 )
次の収益日	( $-0.320 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.31
ATR14	$0.0120 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Forbes Alexandria	Sell	1 000	Ordinary Shares
2024-03-12	Forbes Alexandria	Sell	2 000	Ordinary Shares
2024-02-29	Giroux Richard	Sell	13 500	Ordinary Shares
2024-01-07	Zeldin Robert K	Sell	13 773	Ordinary Shares
2024-01-14	Giroux Richard	Buy	25 000	Ordinary Shares

INSIDER POWER
-5.98
Last 100 transactions
Buy: 8 402 826 \| Sell: 8 030 781

ボリューム相関

長: -0.14 (neutral)

短: -0.39 (neutral)

Signal:(46.293) Neutral

MeiraGTx Holdings PLC 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

MeiraGTx Holdings PLC 相関 - 通貨/商品

-0.30
( neutral )

-0.01
( neutral )

0.00
( neutral )

-0.17
( neutral )

0.82
( strong )

-0.48
( neutral )

MeiraGTx Holdings PLC 財務諸表

Annual	2023
収益:	$14.02M
総利益:	$287 000 (2.05 %)
EPS:	$-1.490

FY	2023
収益:	$14.02M
総利益:	$287 000 (2.05 %)
EPS:	$-1.490

FY	2022
収益:	$15.92M
総利益:	$7.20M (45.21 %)
EPS:	$-3.16

FY	2021
収益:	$37.70M
総利益:	$0.00 (0.00 %)
EPS:	$-1.800

Financial Reports:

No articles found.

MeiraGTx Holdings PLC

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.